Mucopolysaccharidoses (MPS)

Progressive lysosomal storage disorders caused by defects in glycosaminoglycan degradation. Recognition, enzyme and molecular testing, subtype-specific therapy, and the surveillance and perioperative plan that keeps these children safe.

Quick approach

  1. Recognise the pattern: multisystem disease with coarse facial features, hernias, hepatosplenomegaly, recurrent ENT disease, snoring or obstructive sleep apnoea, valvular disease, joint stiffness and dysostosis multiplex. Early developmental plateau or regression with somatic features suggests severe MPS I or neuronopathic MPS II; speech delay then behavioural and sleep problems and regression suggests MPS III. Skeletal-predominant disease with disproportionate short stature and cervical instability suggests MPS IV.
  2. Test in parallel: send urinary GAGs with age-adjusted interpretation plus GAG fractionation or a targeted disaccharide profile by LC-MS/MS where available, and choose enzyme assays from the pattern. Confirm with enzyme activity in leukocytes or cultured fibroblasts and targeted molecular or panel testing. A low dried blood spot result needs diagnostic follow-up, and enzyme, substrate and variant results must correlate to separate disease from pseudodeficiency.
  3. Treat by subtype: laronidase 0.58 mg/kg IV weekly (MPS I) with early HSCT evaluation for severe MPS I; idursulfase 0.5 mg/kg IV weekly for somatic MPS II; elosulfase alfa 2 mg/kg IV weekly (MPS IVA); galsulfase 1 mg/kg IV weekly (MPS VI); vestronidase alfa 4 mg/kg IV every 2 weeks (MPS VII). MPS III is supportive care, with Fayuvi gene therapy FDA-approved for neurologic MPS IIIA with preserved function.
  4. Surveil every system: cardiology with ECG and echocardiogram; ENT, respiratory and polysomnography; spine and mobility with cervical instability and cord compression assessment; audiology and ophthalmology; growth, development, adaptive skills and school function. Tailor intervals to subtype, age and treatment.
  5. Plan for sedation and surgery: flag a difficult airway and cervical cord risk early, review prior anaesthesia, mouth opening, neck mobility, OSA and cardiac status, and coordinate with experienced paediatric anaesthesia, surgery and ENT. Maintain neutral cervical alignment and plan extubation and postoperative observation in advance.

Red flags & when to escalate

New gait deterioration, weakness or bladder dysfunction - suspect spinal cord compression. Stridor at rest, escalating work of breathing or new desaturation - urgent airway and respiratory assessment. A potentially difficult airway and cervical cord risk before any sedation or surgery. Normal total urinary GAGs do not exclude MPS IVA - continue subtype-specific enzyme testing when the phenotype is convincing.

Guidelines, books & articles

Guideline

Aldurazyme (laronidase) - prescribing information

U.S. Food and Drug Administration

U.S. prescribing information for laronidase, dosed 0.58 mg/kg IV once weekly for MPS I.

Open source
Guideline

Naglazyme (galsulfase) - prescribing information

U.S. Food and Drug Administration

U.S. prescribing information for galsulfase, dosed 1 mg/kg IV once weekly for MPS VI.

Open source
Guideline

Fayuvi - prescribing information

U.S. Food and Drug Administration

U.S. prescribing information for Fayuvi gene therapy, FDA-approved for neurologic manifestations of MPS IIIA with preserved neurodevelopmental function.

Open source
Guideline

Mepsevii (vestronidase alfa) - prescribing information

U.S. Food and Drug Administration

U.S. prescribing information for vestronidase alfa, dosed 4 mg/kg IV every 2 weeks for MPS VII.

Open source
Guideline

Mucopolysaccharidoses (MPS) - pediatric clinical guide

Pediatric metabolics / MPS clinical guide · 2026

A pediatric clinical guide to the mucopolysaccharidoses: recognition of the clinical pattern, biochemical and molecular testing, subtype-specific therapy, and surveillance and perioperative planning.

Open source
Guideline

Avlayah (tividenofusp alfa-eknm) - prescribing information

U.S. Food and Drug Administration · 2026

U.S. prescribing information for tividenofusp alfa-eknm, an accelerated-approval enzyme replacement for the neurologic manifestations of MPS II.

Open source
Article

GeneReviews - Mucopolysaccharidosis Type III

GeneReviews, University of Washington · 2024

The Sanfilippo syndromes (MPS IIIA-D): progressive neurocognitive decline with mild somatic features, diagnosis and supportive management.

Open source
Article

GeneReviews - Mucopolysaccharidosis Type IVA

GeneReviews, University of Washington · 2024

Morquio A syndrome: skeletal disease, the role of urinary GAGs and enzyme testing, elosulfase alfa therapy and cervical spine surveillance.

Open source
Article

GeneReviews - Mucopolysaccharidosis Type II

GeneReviews, University of Washington · 2024

The X-linked Hunter syndrome: clinical features, enzyme and molecular testing, idursulfase therapy and the approach to neuronopathic disease.

Open source
Article

GeneReviews - Mucopolysaccharidosis Type I

GeneReviews, University of Washington · 2024

Diagnosis, management and genetic counselling for MPS I, including the severe Hurler spectrum and the role of early haematopoietic stem cell transplantation.

Open source

No sources are linked to this topic yet. Browse the full guidelines and literature list.

Medication doses

Metabolic

Tividenofusp alfa-eknm (Avlayah)

IV weekly escalation: 3 mg/kg for at least 4 weeks, then 7.5 mg/kg for at least 4 weeks, then 15 mg/kg weekly as maintenance if tolerated. Follow the label for transition from idursulfase.

Monitor: CSF heparan sulfate and neurologic function; infusion-associated reactions.

Metabolic

Vestronidase alfa (Mepsevii)

4 mg/kg IV every 2 weeks.

Monitor: Infusion-associated reactions; clinical response and urinary GAGs as directed.

No medication doses are linked to this topic yet. See the full dose reference.